Overview

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Status:
Unknown status

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.

Phase:

Phase 4

Details

Lead Sponsor:

Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.